Eton Pharmaceuticals (ETON) vs uniQure N.V. (QURE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Eton Pharmaceuticals (ETON) has outperformed uniQure N.V. (QURE) over the past year, gaining 161.6% versus a loss of 62.4%. Over five years, ETON leads with a +950.9% price change compared with -25.0% for QURE. Eton Pharmaceuticals is the larger company by market cap ($1.58 billion vs $1.57 billion), about 1.0 times the size.
Eton Pharmaceuticals converts more of its revenue into profit, with a net margin of -5.8% versus -1236.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ETON | QURE |
|---|---|---|
| Share price | $55.21 | $22.59 |
| Market cap | $1.58B | $1.57B |
| 1-day change | +0.84% | +0.22% |
| YTD return | +223.77% | -5.81% |
| 1-year return | +161.59% | -62.41% |
| 5-year return | +950.86% | -25.02% |
| P/E ratio (TTM) | 138.03 | — |
| Forward P/E | 21.40 | — |
| EPS (TTM) | $0.40 | $-4.03 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $79.95M | $16.10M |
| Revenue growth (YoY) | +104.94% | -40.64% |
| Net income (latest FY) | $-4.60M | $-198.97M |
| Gross margin | 53.46% | 89.53% |
| Operating margin | -1.06% | -1151.38% |
| Net margin | -5.75% | -1236.00% |
| 52-week high | $66.37 | $71.50 |
| 52-week low | $14.27 | $8.73 |
| Distance from 52-week high | -16.81% | -68.41% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +28.60% | +175.92% |
| Average volume | 609.36K | 1.97M |
| Shares outstanding | 28.58M | 69.37M |
| Employees | 44 | 221 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ETON has outperformed QURE by 224.0 percentage points over the past year.
- Eton Pharmaceuticals is more profitable, keeping -5.8 cents of every revenue dollar as net income versus -1236.0 cents for uniQure N.V..
- Eton Pharmaceuticals grew revenue faster in its latest fiscal year (+104.94% vs -40.64%).
About Eton Pharmaceuticals
ETON stock →Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1.
Health Care · Biotechnology: Pharmaceutical Preparations · 44 employees
About uniQure N.V.
QURE stock →uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 221 employees
ETON vs QURE FAQ
Which is bigger, Eton Pharmaceuticals or uniQure N.V.?
Eton Pharmaceuticals (ETON) is larger, with a market capitalization of $1.58B compared with $1.57B for uniQure N.V. (QURE).
Which stock has performed better over the past year, ETON or QURE?
ETON returned +161.59% over the past 12 months, compared with -62.41% for QURE (price return, excluding dividends). Past performance does not predict future results.
Are Eton Pharmaceuticals and uniQure N.V. in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.